The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.

Endocr Rev · 2024 · PMC10765167 · PMID 37467734

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

The dual NK1,3R antagonist elinzanetant (40, 80, and 120 mg once daily) administered orally over a full menstrual cycle safely reduced serum LH in a dose-dependent manner, although in a nonsignificant trend ( 21 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.